Effects of GH and Lirglutide on AgRP
NCT05681299
Recruiting
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Te... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
02/10/2025
Locations: Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center, New York, New York
Conditions: Growth Hormone Deficiency, Healthy
Register for Updates
Growth Hormone for the Treatment of Gastroparesis
NCT06803589
Recruiting
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/27/2025
Locations: Mayo Clinic, Phoenix, Arizona +1 locations
Conditions: Gastroparesis
Register for Updates
A Phase 2 Study of Vosoritide in Children with Idiopathic Short Stature
NCT06382155
Recruiting
The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH), in children with idiopathic short stature (ISS).
Gender:
ALL
Ages:
Between 3 years and 10 years
Trial Updated:
01/17/2025
Locations: Center Of Excellence in Diabetes and Endocrinology, Sacramento, California +7 locations
Conditions: Idiopathic Short Stature
Register for Updates
Chromosome 18 Clinical Research Center
NCT00227253
Recruiting
Our vision, that of the researchers at the University of Texas Health Science Center at San Antonio, is that every person with a chromosome 18 abnormality will have an autonomous and healthy life. Our mission is to provide families affected by chromosome 18 abnormalities with comprehensive medical and educational information. Our goals are to provide definitive medical and education resources for the families of individuals with chromosome 18 abnormalities; perform and facilitate groundbreaking... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/03/2024
Locations: University Health Systems Hospital, San Antonio, Texas +1 locations
Conditions: Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Register for Updates
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy
NCT04938466
Completed
The purpose of the study is to compare quality of life, adherence, insulin resistance, body composition and efficacy of long-acting growth hormone (LAGH) to daily growth hormone (DGH) in children with growth hormone deficiency (GHD). These objectives will be evaluated every 6 months for subjects prior to switch from DGH to LAGH, and 6 months after.
Gender:
ALL
Ages:
Between 2 years and 13 years
Trial Updated:
11/18/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Growth Hormone Deficiency, Growth Hormone Treatment
Register for Updates
Human Growth Hormone Injections in the Knee Joint to Treat Osteoarthritis
NCT06354023
Suspended
The goal of this clinical trial is to learn if growth hormone injections can be used to treat osteoarthritis (OA) in the knee. Human studies have shown that repeated injections of human growth hormone leads to the production of articular chondrocytes, which are the cells that make up the cartilage in the knee joint. Restoring cartilage in the knee can alleviate pain, improve function, and postpone the need for a joint replacement procedure. The main questions the study aims to answer are: * Do... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
10/03/2024
Locations: BioShift Life Sciences, Santa Monica, California
Conditions: Osteoarthritis, Knee
Register for Updates
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
NCT03375788
Active Not Recruiting
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may a... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
Register for Updates
Dexamethasone/Pancreatic Clamp P&F
NCT06126354
Withdrawn
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the specific dose-response impact of insulin infusion rate (IIR) on blood glucose levels during a pancreatic clamp study in the setting of dexamethasone-induced insulin resistance. The investigators will recruit participants with a history of overweight/obesity but no history of prediabetes or diabetes. Participants will be rendered temporarily insulin resistant by taking seven doses o... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/09/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Register for Updates
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
NCT00684957
Terminated
The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
Gender:
MALE
Ages:
Between 25 years and 65 years
Trial Updated:
06/21/2024
Locations: Columbia University, College of Physicians and Surgeons, New York, New York
Conditions: Growth Hormone Deficiency
Register for Updates
Growth Hormone Treatment in Children With Phelan McDermid Syndrome
NCT04003207
Completed
Phelan McDermid syndrome (PMS) is a rare genetic form of autism spectrum disorder (ASD) due to deletions or mutations in the SHANK3 gene. This is a pilot open labeled trial of growth hormone therapy in children with PMS targeting social withdrawal and repetitive behavior. This research study will include children with PMS between 2-12 years of age who will receive growth hormone daily for 12 weeks, if found to be eligible. The aim of this study is to evaluate the effect of growth hormone on beha... Read More
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
04/09/2024
Locations: Seaver Autism Center, New York, New York
Conditions: Phelan McDermid Syndrome
Register for Updates
A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty
NCT03981419
Completed
This study will evaluate the safety, tolerability and effect of GRF6021 on clinical recovery parameters in participants undergoing primary hip or knee arthroplasty.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
02/13/2024
Locations: Stanford University Medical Center, Palo Alto, California
Conditions: Postoperative Recovery
Register for Updates
Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Development
NCT00929045
Completed
The purpose of this study is to look at the relationship between growth hormones, and recovery from a TBI - traumatic brain injury. It is believed that a TBI may interfere with the body's ability to produce growth hormones. These hormones may be needed by the body for growth, mental development and sexual maturation.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
12/11/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Traumatic Brain Injury
Register for Updates